1 / 7It was a busy weekend for pharma stocks as four of them — Divi's Laboratories, Fortis Healthcare, Torrent Pharma and Narayana Hrudayalaya — reported their quarterly results.
Here's a look at these names in detail:2 / 7Divi's Laboratories | The pharma company reported its fourth quarter earnings over the weekend, which were largely in-line with estimates.
Its net profit increased 13.4% to ₹751 crore from ₹662 crore last and was above the CNBC-TV18 poll of ₹713 crore.
Its margins contracted to 33% from 34.3% in the year-ago period, while the Street had also estimated 34.2%.
Its revenue increased 75.8%, EBITDA was up 40.2%, profit increased 16.2% and EBITDA margins contracted to 20.8% from 26.1% in the year-ago period.
1 / 7
It was a busy weekend for pharma stocks as four of them — Divi's Laboratories, Fortis Healthcare, Torrent Pharma and Narayana Hrudayalaya — reported their quarterly results. Meanwhile, Lupin marked its entry into the Chinese market, while Glenmark Pharma's US arm settled an anti-trust litigation. Here's a look at these names in detail:
2 / 7
Divi's Laboratories | The pharma company reported its fourth quarter earnings over the weekend, which were largely in-line with estimates. Its net profit increased 13.4% to ₹751 crore from ₹662 crore last and was above the CNBC-TV18 poll of ₹713 crore. Its revenue was up 9.5% at ₹2,831 crore from last year, while the Street had estimated ₹2,859 crore. The company's EBITDA came in a ₹934 crore, up 5.4% from last year and slightly lower than estimates of ₹977 crore. Its margins contracted to 33% from 34.3% in the year-ago period, while the Street had also estimated 34.2%. The margin remained with the company's guided band of 32% to 34%. The stock was down 1.3% at ₹6,794.5 apiece at 9.25 am on Monday. It has risen 5.2% in the past month.
3 / 7
Fortis Healthcare | The company reported a strong set of earnings across all parameters. its net profit increased to 44.6% from ₹265.9 crore, revenue was up 17.8% at ₹2,364.7 crore, EBITDA increased 22.2% from ₹532.3 crore and margins expanded to 22.25% from 21.7% in the year-ago period. Operating profit of the hospitals business was also up 20% from last year. The stock was up 1.9% at ₹978.35 apiece at 9.25 am on Monday. It has giained 8.6% this year, so far.
4 / 7
Torrent Pharma | The company reported a mixed set of earnings in the fourth quarter. Its net profit declined 21.9% to ₹389 crore. Meanwhile, its revenue and EBITDA increased 41.8% and 40.7%, respectively, from the previous year. Its margins contracted to 32% from 33% in the year-ago period. Torrent Pharma's board also recommended a final dividend of ₹9 per share for FY26. The stock was up 3.3% at ₹4,362.4 apiece at 9.30 am on Monday. It has risen 9.8% in the past month and 20.4% this year, so far.
5 / 7
Narayana Hrudayalaya | The company reported its highest ever revenue in the fourth quarter as it integrates its UK business. Its India business witnessed steady growth, while margins dipped from the year-ago period but recovered sequentially. Its revenue increased 75.8%, EBITDA was up 40.2%, profit increased 16.2% and EBITDA margins contracted to 20.8% from 26.1% in the year-ago period. The stock was up 4.6% at ₹1,941 apiece at 9.30 am on Monday. It has risen 8.6% in the past month.
6 / 7
Lupin | The pharma company received approval from the Chinese drug regulator for Oseltamivir Phosphate oral suspension. It is indicated for influenza treatment and prevention, especially for paediatric use. This marks Lupin's product entry into the Chinese market. The stock was up 0.3% at ₹2,288.4 apiece at 9.30 am on Monday. It has gained 8.8% this year, so far.
7 / 7
